CRL vs. VTRS: Charles River Laboratories vs. Viatris Stock Comparison
How do Charles River Laboratories (CRL) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Charles River Laboratories (CRL) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while VTRS is classified in Pharmaceuticals.
| Profile Item | CRL | VTRS |
|---|---|---|
| Name | Charles River Laboratories International, Inc. | Viatris Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 16.17 billion USD | 22.83 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 23, 2000 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | CRL | VTRS |
|---|---|---|
| Total Return (1Y) | 110.83% | 108.98% |
| Total Return (3Y, Annualized) | 27.87% | 36.75% |
| Total Return (5Y, Annualized) | -1.57% | 11.59% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | CRL | VTRS |
|---|---|---|
| Volatility (1Y, Annualized) | 47.81% | 32.53% |
| Beta (5Y) | 1.33 | 0.86 |
| Max Drawdown (5Y) | -74.73% | -45.69% |
| Avg. Volume (3M) | 1.05M | 8.87M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | CRL | VTRS |
|---|---|---|
| Sharpe Ratio (1Y) | 2.23 | 3.22 |
| Sortino Ratio (1Y) | 3.58 | 5.63 |
Profitability
ROE (TTM)
Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Charles River Laboratories (CRL) reports 1.27%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.27%
- Max
- 109.18%
- Q3
- 6.23%
- CRL
- 1.27%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.21%
- Max
- 109.18%
- Q3
- 6.23%
- VTRS
- -4.21%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Charles River Laboratories (CRL) reports 1.01%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01%
- Max
- 18.05%
- Q3
- 4.78%
- CRL
- 1.01%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
-4.13%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- VTRS
- -4.13%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Charles River Laboratories (CRL) at 23.42% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.42%
- Max
- 83.12%
- CRL
- 23.42%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.85%
- Max
- 83.12%
- Q3
- 14.77%
- VTRS
- 13.85%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | CRL | VTRS |
|---|---|---|
| ROE (TTM) | 1.27% | -4.21% |
| ROA (TTM) | 4.74% | 2.91% |
| Net Margin (TTM) | 1.01% | -4.13% |
| Operating Margin (TTM) | 23.42% | 13.85% |
| Gross Margin (TTM) | 35.10% | 41.13% |
Growth
Revenue Growth
Both Charles River Laboratories (CRL) at -0.85% and Viatris (VTRS) at -2.98% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.
EPS Growth
Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.
Growth Metrics
| Metric | CRL | VTRS |
|---|---|---|
| Revenue Growth (YoY) | -0.85% | -2.98% |
| Revenue Growth (3Y CAGR) | 0.33% | -4.20% |
| EPS Growth (YoY) | -1,555.00% | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Charles River Laboratories (CRL) at 1.41 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.41
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- CRL
- 1.41
- Min
- 0.10
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VTRS
- 1.55
- Min
- 0.10
Debt / Equity (MRQ)
Both Charles River Laboratories (CRL) at 0.87 and Viatris (VTRS) at 0.99 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 1.42
- CRL
- 0.87
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.99
- Max
- 1.42
- VTRS
- 0.99
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | CRL | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 1.41 | 1.55 |
| Debt / Equity (MRQ) | 0.87 | 0.99 |
| Net Debt / EBITDA | 2.92 | 2.64 |
Dividends
Dividend Yield (TTM)
Charles River Laboratories (CRL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.53%
- VTRS
- 2.53%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Charles River Laboratories (CRL) pays no dividend (payout 0.00%).
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
960.00%
- VTRS
- 960.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | CRL | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.53% |
| Dividend Payout Ratio (TTM) | 0.00% | 960.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
366.87
- CRL
- 366.87
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- VTRS
- --
P/S Ratio (TTM)
Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Charles River Laboratories (CRL) at 4.07 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.07
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- CRL
- 4.07
- Q1
- 3.01
- Min
- 0.01
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- VTRS
- 1.55
- Min
- 0.01
P/B Ratio (MRQ)
Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Charles River Laboratories (CRL) at 5.01 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.01
- Max
- 13.53
- Q3
- 6.54
- CRL
- 5.01
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
VTRS
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- VTRS
- 1.67
- Min
- -5.59
Valuation Metrics
| Metric | CRL | VTRS |
|---|---|---|
| P/E Ratio (TTM) | 366.87 | -- |
| P/S Ratio (TTM) | 4.07 | 1.55 |
| P/B Ratio (MRQ) | 5.01 | 1.67 |
| Free Cash Flow Yield (TTM) | 2.74% | 13.84% |